Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP Global Revenue | December 18, 2023 | December 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date December 18, 2023 · Filed December 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,949 |
Reported balance
After 2023-12-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-18 · Disposition to issuer · Disposed 3,163 · Balance 48,949 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 46,260 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 5,848 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 46,260 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 5,848 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2023 Filed Dec 19, 2023 21:37 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,163 | $121.85 | $385,412.50 |
DisclosureSEC source: 0001093557-23-000256 · edgardoc.xml · nonDerivative · entry 1 Flynn Paul R · CIK 0001850141 · EVP Global Revenue 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,949 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 46,260 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 5,848 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:36 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,781 | $120.00 | $333,720.00 |
DisclosureSEC source: 0001093557-23-000104 · edgardoc.xml · nonDerivative · entry 1 Flynn Paul R · CIK 0001850141 · EVP Global Revenue 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,112 F1 · shares: On September 9, 2022, Mr. Flynn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Flynn. The shares set forth above were sold pursuant to the 10b5-1 Plan. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Included in this number are 52,112 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,782 | $106.27 | $295,643.14 |
DisclosureSEC source: 0001093557-23-000078 · edgardoc.xml · nonDerivative · entry 4 Flynn Paul R · CIK 0001850141 · EVP Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,893 F3 · shares: On September 9, 2022, Mr. Flynn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Flynn. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 52,112 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 5,643 | $111.40 | $628,624.56 |
DisclosureSEC source: 0001093557-23-000078 · edgardoc.xml · nonDerivative · entry 3 Flynn Paul R · CIK 0001850141 · EVP Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,675 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 52,112 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 5,724 | $111.40 | $637,647.88 |
DisclosureSEC source: 0001093557-23-000078 · edgardoc.xml · nonDerivative · entry 2 Flynn Paul R · CIK 0001850141 · EVP Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,318 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 52,112 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 5,478 | $111.40 | $610,243.72 |
DisclosureSEC source: 0001093557-23-000078 · edgardoc.xml · nonDerivative · entry 1 Flynn Paul R · CIK 0001850141 · EVP Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,042 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 52,112 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 21:00 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 18,776 | $0.00 | $18.78 |
DisclosureSEC source: 0001093557-23-000056 · edgardoc.xml · nonDerivative · entry 1 Flynn Paul R · CIK 0001850141 · EVP Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,520 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 52,112 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| December 08, 2022 Filed Dec 8, 2022 23:07 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 8,988 | $123.50 | $1,110,018.00 |
DisclosureSEC source: 0001093557-22-000181 · edgardoc.xml · nonDerivative · entry 1 Flynn Paul R · CIK 0001850141 · EVP Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,744 F1 · shares: On September 9, 2022, Mr. Flynn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Flynn. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 55,744 unvested restricted stock units, 21,188 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 15,024 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,832 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:24 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 784 | $406.06 | $318,348.45 |
DisclosureSEC source: 0001093557-22-000048 · edgardoc.xml · nonDerivative · entry 4 Flynn Paul R · CIK 0001850141 · EVP Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,183 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 13,936 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,756 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,958 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:24 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 1,114 | $406.06 | $452,347.16 |
DisclosureSEC source: 0001093557-22-000048 · edgardoc.xml · nonDerivative · entry 3 Flynn Paul R · CIK 0001850141 · EVP Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,967 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 13,936 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,756 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,958 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:24 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 1,069 | $406.06 | $434,074.61 |
DisclosureSEC source: 0001093557-22-000048 · edgardoc.xml · nonDerivative · entry 2 Flynn Paul R · CIK 0001850141 · EVP Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,081 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 13,936 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,756 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,958 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 00:24 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 5,297 | $0.00 | $5.30 |
DisclosureSEC source: 0001093557-22-000048 · edgardoc.xml · nonDerivative · entry 1 Flynn Paul R · CIK 0001850141 · EVP Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,150 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 13,936 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,756 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,958 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 2,925 | $0.00 | $2.93 |
DisclosureSEC source: 0001093557-21-000290 · edgardoc.xml · nonDerivative · entry 1 Flynn Paul R · CIK 0001850141 · EVP, Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,853 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock. F2 · balance_after: Included in this number are 13,853 unvested restricted stock units, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,916 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 1,378 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 00:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 626 | $558.33 | $349,514.58 |
DisclosureSEC source: 0001093557-21-000213 · edgardoc.xml · nonDerivative · entry 3 Flynn Paul R · CIK 0001850141 · EVP, Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,928 F3 · shares: On December 11, 2020, Mr. Flynn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Flynn. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 10,928 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,916 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 1,378 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 9 | $541.76 | $4,875.84 |
DisclosureSEC source: 0001093557-21-000213 · edgardoc.xml · nonDerivative · entry 2 Flynn Paul R · CIK 0001850141 · EVP, Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,554 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 10,928 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,916 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 1,378 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 743 | $541.36 | $402,230.48 |
DisclosureSEC source: 0001093557-21-000213 · edgardoc.xml · nonDerivative · entry 1 Flynn Paul R · CIK 0001850141 · EVP, Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,563 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 10,928 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,916 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 1,378 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 20:44 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 758 | $400.00 | $303,200.00 |
DisclosureSEC source: 0001093557-21-000115 · edgardoc.xml · nonDerivative · entry 1 Flynn Paul R · CIK 0001850141 · EVP, Global Revenue 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,306 F1 · shares: On December 11, 2020, Mr. Flynn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Flynn. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 12,306 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,916 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 2,756 of which were granted on March 8, 2019 and shall vest through March 8, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.